Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice

Suppression of Proteoglycan-Induced Arthritis by Anti-CD20 B Cell Depletion Therapy Is Mediated by Reduction in Autoantibodies and CD4+ T Cell Reactivity

(2014) K. Hamel et al.   JOURNAL OF IMMUNOLOGY

Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases

(2012) G. C. Prendergast et al.   CURRENT MEDICINAL CHEMISTRY

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

(2011) M. H. Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases

(2010) Nichola Cooper et al.   BRITISH JOURNAL OF HAEMATOLOGY

Indoleamine 2,3-Dioxygenase

(2010) Hatem Soliman et al.   CANCER JOURNAL

B cells in the pathogenesis and treatment of rheumatoid arthritis

(2010) Bethany Marston et al.   CURRENT OPINION IN RHEUMATOLOGY

Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis

(2010) H. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Immunoregulatory Enzyme IDO Paradoxically Drives B Cell-Mediated Autoimmunity

(2009) G. N. Scott et al.   JOURNAL OF IMMUNOLOGY

Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment

(2008) Petra Roll et al.   ARTHRITIS AND RHEUMATISM